<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04465955</url>
  </required_header>
  <id_info>
    <org_study_id>621-GA-201</org_study_id>
    <nct_id>NCT04465955</nct_id>
  </id_info>
  <brief_title>A Study of NGM621 in Participants With Geographic Atrophy</brief_title>
  <acronym>CATALINA</acronym>
  <official_title>A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled
      study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in the square root of GA lesion area at 48 weeks as measured by fundus autofluorescence (FAF) of NGM621 administered every 4 or 8 weeks compared to Sham.</measure>
    <time_frame>48 Weeks</time_frame>
    <description>The primary efficacy endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence and severity of ocular and systemic adverse events</measure>
    <time_frame>48 Weeks</time_frame>
    <description>The primary safety endpoints</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>NGM621 Treatment Group A (every 4 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM621 single IVT injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM621 Treatment Group C (every 8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM621 single IVT injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Group B (every 4 wks) &amp; D (every 8 wks)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM621</intervention_name>
    <description>NGM621 Dose 1</description>
    <arm_group_label>NGM621 Treatment Group A (every 4 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM621</intervention_name>
    <description>NGM621 Dose 2</description>
    <arm_group_label>NGM621 Treatment Group C (every 8 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Comparator</intervention_name>
    <description>Sham Comparator</description>
    <arm_group_label>Sham Group B (every 4 wks) &amp; D (every 8 wks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Standard luminance BCVA of 49 letters or better using ETDRS charts at the distance of
             4 meters (approximately 20/100 Snellen equivalent) in study eye

          -  If the BCVA letter score is ≥ 79 letters (Snellen equivalent of 20/25 or better), at
             least one GA lesion must be within 250 μm of the foveal center

        Exclusion Criteria:

          -  History of prior intravitreal injection, vitrectomy surgery, submacular surgery, or
             any surgical intervention for AMD. A single intraoperative administration of a
             corticosteroid during cataract surgery for cystoid macular edema prophylaxis at least
             3 months prior to screening is permitted

          -  GA secondary to a condition other than AMD in either eye (e.g., monogenetic macular
             dystrophies (Stargardt disease, cone rod dystrophy), toxic maculopathies)

          -  Any history of or active bacterial, viral, fungal, or parasitic infection in either
             eye in the 3 months prior to randomization

          -  Any history of or active choroidal neovascularization (CNV) in either eye, based on
             fluorescein angiography (FA) and on OCT or OCT-A imaging as assessed by the Central
             Reading Center (CRC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NGM Study Director</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NGM Study Director</last_name>
    <phone>650-243-5555</phone>
    <email>CATALINA@ngmbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Retina Partners</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 112</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 110</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Institute of California</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 103</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 114</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 126</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

